NCT05385991View on ClinicalTrials.gov

Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

August 22, 2023

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)

ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant

Trial Locations (6)

2259

Paratus Research Central Coast, Kanwal

4010

Paratus research Brisbane, Brisbane

Unknown

Paratus Research Sydney, Sydney

Emeritus Research Melbourne, Melbourne

Emeritus Research Sydney, Sydney

ACT 2617

Paratus research Canberra, Canberra

Sponsors

Lead Sponsor

ACM Biolabs
All Listed Sponsors
lead

ACM Biolabs

INDUSTRY

NCT05385991 - Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally. | Biotech Hunter | Biotech Hunter